Baxter International Inc.
NYSE:BAXMedical - Instruments & Supplies
-$1.07 today
- Market cap
- $13.53B
- Beta
- 0.64
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$2.13
- Dividend yield
- 1.03%
Volume 4.01M
Average 7.62M
BAX EBITDA Margin
EBITDA as a percentage of revenue.
Baxter International Inc.NYSE: BAX
EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026
EBITDA Margin holds steady near 16.0%
EBITDA Margin was 16.0% in Q2 FY2026, down 0.4 pp from a year earlier. On a trailing-twelve-month basis it was 6.5%, down 3.0 pp year over year. Over 3 fiscal years it widened by 24.3 pp.
Context
- EBITDA Margin widened in 1 of the last 3 fiscal years.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 11 analysts of 20.9% for the fiscal year ending Dec 2026, up from 6.8% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- 16.0%+5.0 pp QoQ
- Last fiscal yearDec 2025
- 6.8%-3.7 pp YoY
- LTMJun 2026
- 6.5%-3.0 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -0.4 pp | +4.9 pp | +5.3 pp |
| 1 year | -3.7 pp | +14.1 pp | +17.8 pp |
| 3 years | +24.3 pp | +12.7 pp | -11.6 pp |
| 5 years | — | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 6.8%
- Year-over-year change
- -3.7pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6.8% | -3.7pp |
| FY2024 | 2024-12-31 | 10.5% | -6.2pp |
| FY2023 | 2023-12-31 | 16.7% | +34.3pp |
| FY2022 | 2022-12-31 | -17.5% | -35.6pp |
| FY2021 | 2021-12-31 | 18.0% | — |
EBITDA Margin vs competitors
How BAX compares with its peers on the latest reported figures
- BAX's LTM Jun 2026 EBITDA Margin of 6.5% is the lowest of the 5 companies compared; the peer median is 17.9%.
- Its year-over-year change of -3.0 pp is the lowest of 5, against a peer median of +0.3 pp.
- Over three fiscal years its change of +24.3 pp compares with a peer median of +2.8 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Jun 2026 | 19.7% | -0.9 pp | +1.7 pp | |
| LTM Mar 2026 | 18.2% | +2.6 pp | +4.0 pp | |
| LTM Jun 2026 | 17.6% | +1.4 pp | -0.3 pp | |
| LTM Jun 2026 | 11.5% | -2.1 pp | +5.5 pp | |
| LTM Jun 2026 | 6.5% | -3.0 pp | +24.3 pp | |
| Peer median (excluding BAX) | 17.9% | +0.3 pp | +2.8 pp | |
Competitors are the stored peer set for BAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 12.15B | 10.06B | 10.36B | 10.64B | 11.24B |
| Cost of Revenue | 7.43B | 6.51B | 6.21B | 6.65B | 7.87B |
| Gross Profit | 4.72B | 3.55B | 4.15B | 3.98B | 3.38B |
| Gross Margin | 38.9% | 35.3% | 40.1% | 37.5% | 30.1% |
| Research & Development | 531M | 450M | 518M | 590M | 518M |
| Selling, General & Admin | 2.85B | 3.1B | 2.95B | 2.97B | 2.89B |
| Operating Expenses | 3.37B | 6.39B | 3.44B | 3.97B | 3.69B |
| Depreciation & Amortization | 867M | 1.07B | 984M | 997M | 981M |
| EBITDA | 2.19B | (1.76B) | 1.73B | 1.12B | 766M |
| EBITDA Margin | 18.0% | -17.5% | 16.7% | 10.5% | 6.8% |
| Operating Income | 1.35B | (2.85B) | 707M | 14M | (308M) |
| Operating Margin | 11.1% | -28.3% | 6.8% | 0.1% | -2.7% |
| Interest Income | 14M | 19M | 69M | 67M | 52M |
| Interest Expense | 207M | 413M | 508M | 408M | 290M |
| Other Income / Expenses | (234M) | (403M) | (465M) | (303M) | (197M) |
| Income Before Tax | 1.12B | (3.25B) | 242M | (289M) | (505M) |
| Pre-Tax Margin | 9.2% | -32.3% | 2.3% | -2.7% | -4.5% |
| Income Tax Expense | 83M | (135M) | 61M | 37M | 395M |
| Net Income | 1.28B | (2.43B) | 2.66B | (649M) | (957M) |
| Net Margin | 10.6% | -24.2% | 25.6% | -6.1% | -8.5% |
| EPS (Basic) | 2.56 | (4.83) | 5.25 | (1.27) | (1.75) |
| EPS (Diluted) | 2.53 | (4.83) | 5.23 | (1.27) | (1.75) |
| Weighted Avg Shares | 502M | 504M | 506M | 510M | 513M |
| Weighted Avg Shares (Diluted) | 508M | 504M | 506M | 510M | 513M |
Baxter International Inc.
NYSE:BAX
Intrinsic Alpha fair value
Locked
Current Price
$26.16
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.